Update shared on07 Aug 2025
With both Incyte’s future P/E and revenue growth forecasts holding steady, analysts maintained their price target at $80.83.
What's in the News
- FDA approved Monjuvi (tafasitamab-cxix) with rituximab and lenalidomide for relapsed/refractory follicular lymphoma, showing significant improvement in progression-free survival.
- FDA approved Zynyz (retifanlimab-dlwr), both in combination with chemotherapy and as monotherapy, for first-line and subsequent treatment of metastatic/inoperable SCAC; regulatory filings for advanced SCAC submitted in Europe and Japan.
- U.S. FDA extended review period for ruxolitinib cream (Opzelura) in pediatric atopic dermatitis by three months to allow review of additional manufacturing data.
- Incyte and Novartis settled royalty litigation: Incyte will pay $280M to Novartis and see a 50% royalty rate reduction on future U.S. Jakafi sales.
- Bill Meury appointed CEO, succeeding Hervé Hoppenot, who remains an advisor and board member through year-end; Christiana Stamoulis to step down as CFO in September 2025.
Valuation Changes
Summary of Valuation Changes for Incyte
- The Consensus Analyst Price Target remained effectively unchanged, at $80.83.
- The Future P/E for Incyte remained effectively unchanged, at 13.00x.
- The Consensus Revenue Growth forecasts for Incyte remained effectively unchanged, at 8.9% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.